Results 191 to 200 of about 28,689 (318)

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results [PDF]

, 2017
Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Hui‐Ling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi   +13 more
openalex   +1 more source

Ruxolitinib for steroid-resistant acute GVHD [PDF]

Blood, 2020
Regis Peffault de Latour, Antonio Maria Risitano   +1 more
openaire   +4 more sources

Treatment of vitiligo with topical ruxolitinib: a narrative review. [PDF]

Drugs Context
Monteiro E Silva G, Mohamed A, Ferreira C, Torres T.   +3 more
europepmc   +1 more source

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain [PDF]

, 2017
María Teresa Gómez‐Casares, Juan Carlos Hernández‐Boluda, Antonio Jiménez‐Velasco, Joaquín Martínez‐López, María Giovanna Ferrario, Irmina Gozalbo, Joana Gostkorzewicz, R Subirà   +7 more
openalex   +1 more source

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis

British Journal of Haematology, Volume 207, Issue 4, Page 1388-1396, October 2025.
Durable responses based on modified Valent, IWG‐MRT‐ECNM and PPR criteria were predominantly dose‐independent, making dose adjustments due to better tolerability more practicable in daily routine. Gradual tapering of midostaurin, prophylactic treatment with antihistamines and corticosteroids and timely initiation of subsequent therapy can prevent a ...
Johannes Lübke, Nicole Naumann, Timo Brand, Laurenz Steiner, Roland Repp, Georgia Metzgeroth, Alice Fabarius, Wolf‐Karsten Hofmann, Deepti H. Radia, Andreas Reiter, Juliana Schwaab   +10 more
wiley   +1 more source

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia

, 2016
Maximilian Stahl, Mina L. Xu, David P. Steensma, Raajit K. Rampal, Melissa A. Much, Amer M. Zeidan   +5 more
openalex   +2 more sources

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine

British Journal of Pharmacology, Volume 182, Issue 20, Page 5071-5082, October 2025.
Abstract Background and Purpose The JAK–STAT signalling pathway has been extensively spotlighted as a therapeutic target for various diseases. This study assessed the inhibitory effects of a novel small molecule, IN‐115314, on JAK–STAT pathway. Experimental Approach The IC50 values of IN‐115314 for JAK1–pSTAT3 and JAK2–pSTAT5 were determined in canine ...
Jae‐Hun Ahn, Joohwan Kim, Jina Kwak, Jooil Kim, Na‐Young Lee, Heejin Choi, Hee‐Jin Bae, So‐Hyun Cho, Sung‐Gu Jung, Hye‐Mi Kwon, Euna Kwon, Donghyun Kim, Myeongjoong Kim, Daseul Yoon, Seohyun Kim, Bongtae Kim, Byeong‐Cheol Kang   +16 more
wiley   +1 more source

Successful Treatment of Childhood Nail Lichen Planus with Ruxolitinib Cream: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Sheng A, Hu W, Xu A.
europepmc   +1 more source

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

, 2016
Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Haifa Kathrin Al‐Ali, Lynda Foltz, Michael T. Montgomery, William Sun, P. Gopalakrishna, H. Kantarjian, Srđan Verstovšek   +9 more
openalex   +1 more source

Recommendations on the use of ruxolitinib for the treatment of myelofibrosis [PDF]

, 2017
Timothy Devos, Dominik Selleslag, Pierre Zachée, Fleur Samantha Benghiat   +3 more
openalex   +1 more source